Vitor Mendes
University of Cambridge
43 Papers
256 Citations
Vitor Mendes is an academic researcher from University of Cambridge. The author has contributed to research in topics: Mycobacterium tuberculosis & Biology. The author has an hindex of 18, co-authored 39 publications. Previous affiliations of Vitor Mendes include University of Coimbra.
Chat about Author
Papers
Arginine-deprivation–induced oxidative damage sterilizes Mycobacterium tuberculosis
Sangeeta Tiwari,Andries J. van Tonder,Catherine Vilchèze,Catherine Vilchèze,Vitor Mendes,Sherine E. Thomas,Adel A. Malek,Bing Chen,Mei Chen,John Kim,Tom L. Blundell,Julian Parkhill,Brian Weinrick,Michael Berney,William R. Jacobs,William R. Jacobs +15 more
TL;DR: In vivo essentiality of the de novo arginine biosynthesis pathway for Mtb is revealed and a promising drug target space for combating tuberculosis is proposed.
94
Bacillus foraminis sp. nov., isolated from a non-saline alkaline groundwater.
Igor Tiago,Cléo T. G. V. M. T. Pires,Vitor Mendes,Paula V. Morais,Milton S. da Costa,António Veríssimo +5 more
TL;DR: On the basis of the phylogenetic analyses and the distinct phenotypic characteristics, strain CV53T represents a novel species within the genus Bacillus, for which the name Bacillus foraminis sp.
57
Organic solutes in Rubrobacter xylanophilus: the first example of di-myo-inositol-phosphate in a thermophile.
Nuno Empadinhas,Vitor Mendes,Catarina Simões,Maria S. Santos,Ana Mingote,Pedro Lamosa,Helena Santos,Milton S. da Costa +7 more
TL;DR: This is the first report of MG and DIP in an actinobacterium and includes the identification of the new solute di-N-acetyl-glucosamine phosphate, which was always present and increased with the growth temperature.
Targeting tuberculosis using structure-guided fragment-based drug design.
Vitor Mendes,Tom L. Blundell +1 more
TL;DR: The progress of the group and others is described, the most recent successes and challenges in developing compounds with antimycobacterial activity are examined, and the approach has been used sparsely in the tuberculosis field.
45
Structure-guided fragment-based drug discovery at the synchrotron: screening binding sites and correlations with hotspot mapping.
Sherine E. Thomas,P.M. Collins,Rory Hennell James,Rory Hennell James,Vitor Mendes,Sitthivut Charoensutthivarakul,Chris J Radoux,Chris Abell,Anthony G. Coyne,R. Andres Floto,R. Andres Floto,Frank von Delft,Tom L. Blundell +12 more
TL;DR: Advances in X-ray fragment screening and the challenge of identifying sites where fragments not only bind but can be chemically elaborated while retaining their positions and binding modes are discussed.
40